| P50 | author | Alessandra Luchini | Q40221691 |
| P2093 | author name string | L A Liotta | |
| | E F Petricoin | |
| | S Rucker | |
| | A Reeder | |
| | A Luchini | |
| | B H Espina | |
| | C Fredolini | |
| | F Meani | |
| P2860 | cites work | PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor | Q22254096 |
| | Analysis of albumin-associated peptides and proteins from ovarian cancer patients | Q24314877 |
| | The human plasma proteome: history, character, and diagnostic prospects | Q28218148 |
| | High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures | Q33221138 |
| | A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples | Q33282971 |
| | Temperature-sensitive aqueous microgels | Q33851273 |
| | Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation | Q33882805 |
| | Proteomics for cancer biomarker discovery. | Q34141349 |
| | PDGFRA activating mutations in gastrointestinal stromal tumors. | Q34169772 |
| | Dye-ligand affinity systems | Q34428291 |
| | Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 |
| | Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. | Q34554628 |
| | Platelet-derived growth factor signaling and human cancer | Q35051106 |
| | Blue dextran-sepharose: an affinity column for the dinucleotide fold in proteins | Q35070514 |
| | Protein microarrays: molecular profiling technologies for clinical specimens | Q35574627 |
| | The PDGF family: four gene products form five dimeric isoforms | Q35811076 |
| | Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. | Q36153740 |
| | Sampling and analytical strategies for biomarker discovery using mass spectrometry | Q36506723 |
| | Banking of biological fluids for studies of disease-associated protein biomarkers | Q36919974 |
| | Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma | Q37109503 |
| | Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles | Q40497895 |
| | The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. | Q44002734 |
| | Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer | Q45018087 |
| | Interaction of native alpha-cyclodextrin, beta-cyclodextrin and gamma-cyclodextrin and their hydroxypropyl derivatives with selected organic low molecular mass compounds at elevated and subambient temperature under RP-HPLC conditions. | Q46532600 |
| | Enantioseparation of dopa and related compounds by cyclodextrin-modified microemulsion electrokinetic chromatography | Q46552658 |
| | Methyl-beta-cyclodextrin, a specific cholesterol-binding agent, inhibits melanogenesis in human melanocytes through activation of ERK. | Q46597393 |
| | Differences among techniques for high-abundant protein depletion | Q46625303 |
| | Water-soluble fluorescent boronic acid compounds for saccharide sensing: substituent effects on their fluorescence properties | Q46809723 |
| | A method for the selective isolation and enrichment of carrier protein-bound low-molecular weight proteins and peptides in the blood | Q47303706 |
| | Dihydrofolate reductases from chicken liver and Lactobacillus casei bind Cibacron blue F3GA in different modes and at different sites. | Q50941882 |
| | Fractionation of serum components using nanoporous substrates. | Q51941657 |
| | Perspective: A Program to Improve Protein Biomarker Discovery for Cancer† | Q58179608 |
| | Platelet-derived growth factor in vivo: levels, activity, and rate of clearance | Q70222078 |
| | A two-step purification procedure for α2 -macroglobulin based on pseudo-ligand affinity chromatography | Q72662822 |
| | Effects of storage time and exogenous protease inhibitors on plasma protein levels | Q80064761 |
| P433 | issue | 2 | |
| P921 | main subject | nanoparticle | Q61231 |
| | biomarker | Q864574 |
| P304 | page(s) | 133-141 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Current Molecular Medicine | Q5195065 |
| P1476 | title | Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery | |
| P478 | volume | 10 | |